|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011603,
umls-concept:C0026336,
umls-concept:C0031891,
umls-concept:C0073561,
umls-concept:C0185125,
umls-concept:C0205341,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0442027,
umls-concept:C1280500,
umls-concept:C1314792,
umls-concept:C1521801,
umls-concept:C1522424,
umls-concept:C1527415,
umls-concept:C2936609
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2006-2-28
|
|
pubmed:abstractText |
The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB). BALB/c mice were sensitized with 0.3% w/v TNCB applied to the ear on day -7, followed by application three times a week from day 0. Rolipram, prednisolone and cyclosporine A were administered orally once daily from day 0 to 21. Rolipram at a dose of 10 mg/kg/day significantly inhibited the ear thickness and the increase in cytokine levels and enzyme activity in the ear. Interleukin (IL)-4 production was markedly decreased in cervical lymph node cells from animals treated with rolipram at a dose of 10 mg/kg/day. Prednisolone and cyclosporine A significantly reduced ear thickness. These compounds significantly decreased the total cell and lymphocyte number of the cervical lymph nodes. Furthermore, prednisolone markedly suppressed body weight gain, and cyclosporine A significantly increased the serum total IgE concentration compared with that in the vehicle-treated control. Rolipram, unlike prednisolone and cyclosporine A, did not influence body weight and the total IgE concentration in the serum. The present results suggest that the PDE4 inhibitor is a promising oral medicine for the treatment of chronic skin inflammatory diseases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin E,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Peroxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Picryl Chloride,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Rolipram
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0014-2999
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
532
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
128-37
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16442096-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:16442096-Administration, Oral,
pubmed-meshheading:16442096-Animals,
pubmed-meshheading:16442096-Anti-Inflammatory Agents,
pubmed-meshheading:16442096-Cell Count,
pubmed-meshheading:16442096-Cyclic Nucleotide Phosphodiesterases, Type 4,
pubmed-meshheading:16442096-Cyclosporine,
pubmed-meshheading:16442096-Cytokines,
pubmed-meshheading:16442096-Dermatitis,
pubmed-meshheading:16442096-Disease Models, Animal,
pubmed-meshheading:16442096-Dose-Response Relationship, Drug,
pubmed-meshheading:16442096-Ear, Inner,
pubmed-meshheading:16442096-Immunoglobulin E,
pubmed-meshheading:16442096-Immunosuppressive Agents,
pubmed-meshheading:16442096-Lymph Nodes,
pubmed-meshheading:16442096-Male,
pubmed-meshheading:16442096-Mice,
pubmed-meshheading:16442096-Mice, Inbred BALB C,
pubmed-meshheading:16442096-Peroxidase,
pubmed-meshheading:16442096-Phosphodiesterase Inhibitors,
pubmed-meshheading:16442096-Picryl Chloride,
pubmed-meshheading:16442096-Prednisolone,
pubmed-meshheading:16442096-Rolipram,
pubmed-meshheading:16442096-T-Lymphocytes,
pubmed-meshheading:16442096-Time Factors,
pubmed-meshheading:16442096-Weight Gain
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
|
|
pubmed:affiliation |
Department of Allergy Research, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co. Ltd. 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Sizuoka 411-8731, Japan. daisuke.harada@kyowa.co.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
